Latest Information Update: 19 Jun 2001
At a glance
- Originator Phanos Technologies
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jun 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 25 Jan 1996 Preclinical development for Cancer in USA (Unknown route)